Science: IBS Acute Pain Treatment: Fast-Acting Relief for IBS Pain

ROSE-010, a novel short-acting GLP-1 receptor agonist, has demonstrated significant pain relief in IBS patients in clinical studies.
  • Clinical Trial Results: In a placebo-controlled study evaluating two doses of ROSE-010, patients were classified as ‘responders’ if they experienced at least 50% pain reduction, averaged over the full hour post-treatment. Twice as many patients met this strict responder definition with ROSE-010 compared to placebo, meaning pain relief had to be sustained across the hour—not just at a single time point.
  • Subgroup Analysis: Further investigation revealed ROSE-010 was most effective in IBS-C and IBS-M patients and particularly in women.
  • Action: ROSE-010 targets GLP-1 receptors in the gut, which play a role in gut sensitivity, pain perception, and smooth muscle relaxation.
  • Planned Studies: A Phase IIb placebo-controlled study will evaluate ROSE-010 in IBS-C and IBS-M patients, with participants self-injecting and recording pain levels. This will be followed by a Phase III trial.

Click link to publication Hellstrom et al

Click link to publication Touny et al_2022.pdf

GI Transit Study

Impact on Gut Motility

ROSE-010’s effects on gastrointestinal transit were studied in women with IBS-C, showing key benefits for motility symptoms:

  • Findings: ROSE-010 delayed small intestine transit time while increasing colon transit time, indicating potential relief for IBS-C patients experiencing constipation.
  • Clinical Implication: This supports the idea that ROSE-010 not only relieves pain but may also help to normalize gut motility in IBS-C.

Click link to publication Camilleri et al

The Science Behind ROSE-010: A New Approach to IBS Pain Relief

GLP-1 is a small peptide hormone naturally produced in the small intestine in response to food. It plays a key role in:

  • Gut motility & digestion (slowing gastric emptying)
  • Regulating appetite & glucose metabolism
  • Perception of visceral pain

The IBS-GLP-1 Connection:

IBS patients (especially IBS-C) have lower GLP-1 levels & receptor expression.  This deficiency is linked to increased pain severity.

How ROSE-010 Works in IBS: Targeted, On-Demand Pain Relief

ROSE-010 mimics natural GLP-1 with an optimized, short-acting profile:

  • Fast-acting – ( Begins working in 20 minutes )
  • Short duration ( Clears in a few hours )
  • Use only when needed during acute episodes for pain resolution

Clinical Validation: Proven IBS Pain Relief

In Phase 2a Trial Results (Hellström et al.), ROSE-010

  • 166 patients with IBS pain (placebo-controlled study)
  • Twice as many patients responded to ROSE-010 vs. placebo
  • Most effective in IBS-C & IBS-M patients
  • Well-tolerated with no major side effects

Phase 2a results

ROSE-010’s Effect on IBS Motility

GI Transit Study (Camilleri et al.) Findings:

  • Small intestine transit time increased
  • Colonic transit time decreased → Potential to improve IBS-C & IBS -M symptoms

What’s Next? The Future of ROSE-010 in IBS

Upcoming Phase 2b Trial:

  • Focus on IBS-C & IBS-M (most responsive groups)
  • Patients will self-inject during pain attacks
  • Pain measured using standardized numeric pain scale